Tech Company Financing Transactions
Epiomed Therapeutics Funding Round
Epiomed Therapeutics, operating out of Irvine, scored investment capital from private investors.
Transaction Overview
Company Name
Announced On
6/8/2011
Transaction Type
Venture Equity
Amount
Unknown
Round
Series A
Investors
Proceeds Purpose
Proceeds from this financing are anticipated to be used for development of Epiomed's lead anti-emetic compound, designated "ETI-0001" with a Phase 1/2 clinical assessment of ETI-0001 anticipated starting in 1Q 2012.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
25 Mauchly 316
Irvine, CA 92618
USA
Irvine, CA 92618
USA
Phone
Website
Email Address
Overview
Epiomed Therapeutics is focused on the discovery and development of novel anti-emetic compounds for both the human and veterinary markets.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Helton
Chief Operating Officer
Ernest Pfadenhauer
Browse more venture capital transactions:
Prev: 6/8/2011: VirtuOz venture capital transaction
Next: 6/8/2011: Telltale venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs